New Study Looks at Selumetinib for Treating Differentiated Thyroid Cancer

Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.

Source: CancerNetwork - November 13, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news